The ophthalmologist called the probability of the risk of vision loss from "Ozempika"

The probability of vision loss from "Ozempika" is estimated as no more than one case per 10,000. Such data was provided on November 15 by ophthalmologist, ophthalmic surgeon of the highest category of VISTA clinic Egor Kostyukov.

"The absolute risk is very low, even according to conservative estimates, this is no more than one additional case per 10,000 patients per year. Therefore, in my opinion, this is not a reason to refuse treatment prescribed according to indications," the specialist explained in an interview with RBC.

According to him, a warning about the possible risk of vision loss when using GLP-1 drugs, including Ozempik, requires attention, but it does not mean that the prescribed treatment should be discontinued. Kostyukov explained that the initial data on a possible connection related to semaglutide, the active substance of Ozempika. At the same time, he considers it justified to extend the warning to the entire GLP-1 class.

The specialist recommends especially careful monitoring of vision for people with diabetes, high blood pressure and obstructive sleep apnea. In addition, a rapid decrease in sugar can temporarily worsen pre-existing diabetic retinopathy.

In case of sudden deterioration of vision in one eye or loss of part of the image, Kostyukov recommended contacting an ophthalmologist on the same day. The absence of pain should not be a reason to postpone the visit, as the disorder may persist forever.

Nutritionist Pavel Baranov also confirmed on November 13 that the risk of damage to the optic nerve due to taking Ozempik is considered extremely low and significantly lower than the risk of complications from uncontrolled diabetes. According to Baranov, the causal relationship between taking the drug and damage to the optic nerve has not yet been proven.

In the United States, more than 4,000 lawsuits against manufacturers of Ozempika and similar drugs have begun to be considered. The plaintiffs complain of side effects, among which disorders of the gastrointestinal tract predominate, in particular gastroparesis. 278 lawsuits relate to visual impairments, and another 4082 cases relate to gastrointestinal problems.